Rachael P. Dippold, Ph.D.
Associate
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Rachael P. Dippold, Ph.D., is an associate at Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. Rachael employs a decade of experience in providing strategic counseling and patent prosecution services for clients of various sizes and stages. As a patent attorney with a doctorate in molecular biology, she draws on her technical experience to assist clients in matters related to a wide range of life science technologies, including biologics, pharmaceuticals, gene therapy, vaccines, biotechnology, diagnostics, and agricultural science. Rachael leverages her experience in drug regulation and policy development while at the U.S. Food and Drug Administration in counseling pharmaceutical and biologics clients. She also draws on her experience with adversarial patent actions, including BPCIA litigation.
Recent Articles by Rachael P. Dippold, Ph.D.
Counting Patents, Not Progress: Another Misdiagnosis by I-MAK
An April 2025 report from the Initiative for Medicines, Access & Knowledge (I-MAK) titled, “The Heavy Price of GLP-1 Drugs,” presents grossly misleading information regarding the patent protection for semaglutide products (marketed by Novo Nordisk under the trademarks Ozempic, Rybelsus, and Wegovy) and tirzepatide products (marketed by Eli Lilly under the trademarks Mounjaro and Zepbound). The report accuses Novo Nordisk and Eli Lilly of engaging in patent abuse to extend protection for their products. This accusation is predicated on I-MAK’s assertion that these companies own large numbers of patents covering their respective products. But, as the United States Patent and Trademark Office (USPTO) noted in its recent Drug Patent and Exclusivity Study, “simply quantifying raw numbers of patents and exclusivities is an imprecise way to measure the intellectual property landscape of a drug product because not every patent or exclusivity has the same scope.”